The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...